SG11202102006YA - Crystalline forms of a quinazole compound and its hydrochloride salts - Google Patents
Crystalline forms of a quinazole compound and its hydrochloride saltsInfo
- Publication number
- SG11202102006YA SG11202102006YA SG11202102006YA SG11202102006YA SG11202102006YA SG 11202102006Y A SG11202102006Y A SG 11202102006YA SG 11202102006Y A SG11202102006Y A SG 11202102006YA SG 11202102006Y A SG11202102006Y A SG 11202102006YA SG 11202102006Y A SG11202102006Y A SG 11202102006YA
- Authority
- SG
- Singapore
- Prior art keywords
- quinazole
- compound
- crystalline forms
- hydrochloride salts
- hydrochloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862731500P | 2018-09-14 | 2018-09-14 | |
PCT/IB2019/057720 WO2020053816A1 (en) | 2018-09-14 | 2019-09-12 | Crystalline forms of a quinazole compound and its hydrochloride salts |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102006YA true SG11202102006YA (en) | 2021-04-29 |
Family
ID=69776732
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102006YA SG11202102006YA (en) | 2018-09-14 | 2019-09-12 | Crystalline forms of a quinazole compound and its hydrochloride salts |
SG11202101712XA SG11202101712XA (en) | 2018-09-14 | 2019-09-12 | Kits and methods for treating cancers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101712XA SG11202101712XA (en) | 2018-09-14 | 2019-09-12 | Kits and methods for treating cancers |
Country Status (16)
Country | Link |
---|---|
US (2) | US20220040180A1 (en) |
EP (2) | EP3849557A4 (en) |
JP (2) | JP2022500456A (en) |
KR (2) | KR20210046818A (en) |
CN (2) | CN112770758A (en) |
AR (2) | AR116669A1 (en) |
AU (2) | AU2019340598A1 (en) |
BR (2) | BR112021004527A2 (en) |
CA (2) | CA3111062A1 (en) |
IL (2) | IL281167A (en) |
MX (2) | MX2021002875A (en) |
PH (2) | PH12021550432A1 (en) |
SG (2) | SG11202102006YA (en) |
TW (2) | TW202023562A (en) |
UY (2) | UY38374A (en) |
WO (2) | WO2020053816A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022500456A (en) | 2018-09-14 | 2022-01-04 | ハンミ ファーマシューティカル カンパニー リミテッド | Crystal form of quinazoline compound and its hydrochloride |
CN114642728A (en) * | 2021-06-02 | 2022-06-21 | 德琪(浙江)医药科技有限公司 | Pharmaceutical application of mTOR inhibitor and pharmaceutical composition thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064762A2 (en) * | 2003-01-21 | 2004-08-05 | S.S.C.I. Inc. | Novel cocrystallization |
KR100735639B1 (en) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | Quinazoline derivatives inhibiting the growth of cancer cell and preparation thereof |
ATE521603T1 (en) * | 2005-02-26 | 2011-09-15 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS |
EP2038266A2 (en) * | 2006-05-31 | 2009-03-25 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
EP2054393A1 (en) * | 2006-07-28 | 2009-05-06 | Synthon B.V. | Crystalline erlotinib |
KR20100014512A (en) * | 2007-02-21 | 2010-02-10 | 낫코 파마 리미티드 | Novel polymorphs of erlotinib hydrochloride and method of preparation |
TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
KR101217526B1 (en) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof |
KR101317809B1 (en) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant |
KR101272613B1 (en) * | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxy quinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one hydrochloride and intermediates used therein |
EP2964638B1 (en) * | 2013-03-06 | 2017-08-09 | Astrazeneca AB | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
WO2015154725A1 (en) * | 2014-04-11 | 2015-10-15 | 四川海思科制药有限公司 | Quinazoline derivative and preparation method and use in medicine thereof |
ES2841600T3 (en) * | 2015-10-19 | 2021-07-08 | Sunshine Lake Pharma Co Ltd | Di (methanesulfonic acid) salt of (3-chloro-4-fluoro-phenyl) - (6 - ((4aR, 7aS) -3- (hexahydro- (1,4) dioxino (2,3-c) pyrrole- 6-yl) -propoxy) -7-methoxy-quinazolin-4-yl) -amine and crystalline form of the monohydrate (an EGFR inhibitor) |
EP3528798A4 (en) * | 2016-10-19 | 2020-10-21 | United States Government as Represented by The Department of Veterans Affairs | Compositions and methods for treating cancer |
EP3541832A4 (en) * | 2016-11-17 | 2020-09-30 | Board of Regents, The University of Texas System | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations |
JP2022500456A (en) | 2018-09-14 | 2022-01-04 | ハンミ ファーマシューティカル カンパニー リミテッド | Crystal form of quinazoline compound and its hydrochloride |
-
2019
- 2019-09-12 JP JP2021514419A patent/JP2022500456A/en active Pending
- 2019-09-12 JP JP2021513941A patent/JP2022500416A/en active Pending
- 2019-09-12 WO PCT/IB2019/057720 patent/WO2020053816A1/en unknown
- 2019-09-12 US US17/275,290 patent/US20220040180A1/en not_active Abandoned
- 2019-09-12 WO PCT/US2019/050843 patent/WO2020056156A1/en unknown
- 2019-09-12 EP EP19860538.8A patent/EP3849557A4/en not_active Withdrawn
- 2019-09-12 CN CN201980060160.6A patent/CN112770758A/en active Pending
- 2019-09-12 EP EP19859287.5A patent/EP3849964A4/en active Pending
- 2019-09-12 KR KR1020217010957A patent/KR20210046818A/en unknown
- 2019-09-12 SG SG11202102006YA patent/SG11202102006YA/en unknown
- 2019-09-12 MX MX2021002875A patent/MX2021002875A/en unknown
- 2019-09-12 MX MX2021002876A patent/MX2021002876A/en unknown
- 2019-09-12 AU AU2019340598A patent/AU2019340598A1/en active Pending
- 2019-09-12 KR KR1020217010772A patent/KR20210061371A/en unknown
- 2019-09-12 US US17/275,382 patent/US11883402B2/en active Active
- 2019-09-12 BR BR112021004527-9A patent/BR112021004527A2/en not_active Application Discontinuation
- 2019-09-12 CA CA3111062A patent/CA3111062A1/en active Pending
- 2019-09-12 CN CN201980060170.XA patent/CN112823153A/en active Pending
- 2019-09-12 CA CA3110369A patent/CA3110369A1/en active Pending
- 2019-09-12 SG SG11202101712XA patent/SG11202101712XA/en unknown
- 2019-09-12 AU AU2019337640A patent/AU2019337640A1/en not_active Abandoned
- 2019-09-12 BR BR112021004546-5A patent/BR112021004546A2/en unknown
- 2019-09-16 TW TW108133291A patent/TW202023562A/en unknown
- 2019-09-16 AR ARP190102610A patent/AR116669A1/en unknown
- 2019-09-16 UY UY0001038374A patent/UY38374A/en unknown
- 2019-09-16 AR ARP190102611A patent/AR116406A1/en unknown
- 2019-09-16 TW TW108133290A patent/TW202027750A/en unknown
- 2019-09-16 UY UY0001038375A patent/UY38375A/en not_active Application Discontinuation
-
2021
- 2021-03-01 IL IL281167A patent/IL281167A/en unknown
- 2021-03-01 PH PH12021550432A patent/PH12021550432A1/en unknown
- 2021-03-01 IL IL281168A patent/IL281168A/en unknown
- 2021-03-03 PH PH12021550456A patent/PH12021550456A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283860A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
EP3619208C0 (en) | Crystalline forms of a jak inhibitor compound | |
IL287668A (en) | Crystalline forms of a btk inhibitor | |
IL283663A (en) | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | |
IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
PL3613733T3 (en) | Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1h-pyrazol-5-ol hydrochloride | |
EP3558315A4 (en) | Crystalline salts and polymorphs of a p2x3 antagonist | |
IL289929A (en) | Crystalline forms of a cd73 inhibitor | |
IL281168A (en) | Crystalline forms of a quinazole compound and its hydrochloride salts | |
IL282996A (en) | Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator | |
IL282454A (en) | Crystalline salts of a plasma kallikrein inhibitor | |
IL274027A (en) | Crystalline salts of a b-raf kinase inhibitor | |
IL272835A (en) | The salts of a compound and the crystalline forms thereof | |
IL278054A (en) | The crystalline forms of a compound | |
IL279953A (en) | Crystalline forms of a lta4h inhibitor | |
IL292206A (en) | The salts of a compound and the crystalline forms thereof | |
SG11202107225SA (en) | Crystalline form of a cdk inhibitor | |
SG11202009262VA (en) | Salts of compounds and crystals thereof | |
IL274758A (en) | Crystalline polymorphs of pracinostat and pracinostat salts | |
HK1252841A1 (en) | Crystalline forms of hydrochloride salts of thienopyrimidine compound | |
GB201912411D0 (en) | Crystalline forms of ivosidenib | |
IL285763A (en) | Solid polymorphs of a flna-binding compound and its hydrochloride salts | |
SG11202105355XA (en) | Crystalline salts of corydalmine | |
EP3630750A4 (en) | The salts of a compound and the crystalline forms thereof | |
IL292847A (en) | Crystalline forms of a magl inhibitor |